Latigo Biotherapeutics IPO
Latigo Biotherapeutics is a private biotechnology company developing therapeutic treatments. The company operates in the biopharmaceutical development space, though specific details about its drug pipeline and target indications have not been widely disclosed. Investor interest would typically center on clinical data and regulatory progress.
Key Facts
| Industry | Biotechnology |
| Funding | Raised $345.6 million through IPO completed August 7, 2026 (upsized offering priced at $18 per share, the high end of range) |
About Latigo Biotherapeutics
Latigo Biotherapeutics is a biopharmaceutical company focused on developing novel therapeutics. The company's specific therapeutic areas, drug candidates, and stage of development have not been extensively disclosed in public sources.
As a private biotechnology company, Latigo would need to provide comprehensive information about its pipeline, clinical trial results, intellectual property, and commercial strategy as part of any IPO process. The success of a potential public offering would depend heavily on the strength of its scientific data and market opportunity for its therapeutic programs.
IPO Status
Latigo Biotherapeutics successfully completed its initial public offering on August 7, 2026, and began trading on Nasdaq under the ticker symbol LTGO. The company priced its upsized IPO at $18 per share, at the high end of its expected range, raising approximately $345.6 million. This exceeded the company's original target of $247-288 million. The IPO was oversubscribed and shares jumped 17% in their trading debut, reflecting strong investor demand for the clinical-stage pain management company. The biotech is developing non-opioid pain relief therapies, with its lead drug candidate being a Nav1.8 inhibitor that competes directly with Vertex Pharmaceuticals' Journavx in the multi-billion dollar pain management market. The company's Nav1.8 inhibitor represents a novel approach to pain management that avoids the addiction risks associated with opioid-based treatments. The IPO proceeds will be used to advance Latigo's pain pipeline, with the lead drug candidate reportedly nearing Phase 3 clinical trials, backed by Phase II data that helped drive investor confidence in the offering.
Competitors
Frequently Asked Questions
Does Latigo Biotherapeutics have a stock?
No, Latigo Biotherapeutics has not completed an IPO. The company is currently private, though it is expected to consider going public at some point. Sign up for alerts to stay informed.
When is the Latigo Biotherapeutics IPO date?
Latigo Biotherapeutics has not announced an IPO date. No official filing has been made, and the timeline for a potential offering remains unclear. Sign up for alerts to stay informed.
How can I buy Latigo Biotherapeutics stock?
Latigo Biotherapeutics shares are not publicly available for purchase as the company is privately held. If the company goes public, shares would become available through traditional brokerage platforms. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts